Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

Choon Kee Lee, M. Zangari, B. Barlogie, A. Fassas, F. van Rhee, R. Thertulien, G. Talamo, F. Muwalla, E. Anaissie, K. Hollmig, G. Tricot

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

To evaluate the role of high-dose melphalan and autologous transplant (AT) in reversing dialysis-dependent renal failure, 59 patients still on dialysis at the time of AT were analyzed. A total of 37 patients had been on dialysis ≤6 months. A 5-year event-free and overall survival rate of all patients after AT was 24 and 36%, respectively. Of 54 patients evaluable for renal function improvement, 13 (24%) became dialysis independent at a median of 4 months after AT (range: 1-16). Dialysis duration ≤ 6 months prior to first AT and pre-transplant creatinine clearance >10 ml/min were significant for renal function recovery: 12 of 36 (33%) ≤ 6 months vs one of 18 patients (6%) > 6 months on dialysis recovered renal function; 10 of 26 (38%) with > 10 ml/min vs three of 28 (11%) with ≤ 10 ml/min of creatinine clearance (both P < 0.05). Quality of response after autotransplant was also significant: 12 of 31 (39%) being greater than partial remission after AT vs one of 21 patients (5%) attaining partial remission or less became independent of dialysis (P < 0.05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course.

Original languageEnglish (US)
Pages (from-to)823-828
Number of pages6
JournalBone Marrow Transplantation
Volume33
Issue number8
DOIs
StatePublished - Apr 2004

Fingerprint

Autografts
Renal Insufficiency
Dialysis
Therapeutics
Creatinine
Kidney
Melphalan
Recovery of Function
Disease-Free Survival
Renal Dialysis
Survival Rate
Transplants

Keywords

  • Multiple myeloma
  • Renal failure
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. / Lee, Choon Kee; Zangari, M.; Barlogie, B.; Fassas, A.; van Rhee, F.; Thertulien, R.; Talamo, G.; Muwalla, F.; Anaissie, E.; Hollmig, K.; Tricot, G.

In: Bone Marrow Transplantation, Vol. 33, No. 8, 04.2004, p. 823-828.

Research output: Contribution to journalArticle

Lee, CK, Zangari, M, Barlogie, B, Fassas, A, van Rhee, F, Thertulien, R, Talamo, G, Muwalla, F, Anaissie, E, Hollmig, K & Tricot, G 2004, 'Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant', Bone Marrow Transplantation, vol. 33, no. 8, pp. 823-828. https://doi.org/10.1038/sj.bmt.1704440
Lee, Choon Kee ; Zangari, M. ; Barlogie, B. ; Fassas, A. ; van Rhee, F. ; Thertulien, R. ; Talamo, G. ; Muwalla, F. ; Anaissie, E. ; Hollmig, K. ; Tricot, G. / Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 8. pp. 823-828.
@article{7a1b58c18d93430e88ee03ec686b3677,
title = "Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant",
abstract = "To evaluate the role of high-dose melphalan and autologous transplant (AT) in reversing dialysis-dependent renal failure, 59 patients still on dialysis at the time of AT were analyzed. A total of 37 patients had been on dialysis ≤6 months. A 5-year event-free and overall survival rate of all patients after AT was 24 and 36{\%}, respectively. Of 54 patients evaluable for renal function improvement, 13 (24{\%}) became dialysis independent at a median of 4 months after AT (range: 1-16). Dialysis duration ≤ 6 months prior to first AT and pre-transplant creatinine clearance >10 ml/min were significant for renal function recovery: 12 of 36 (33{\%}) ≤ 6 months vs one of 18 patients (6{\%}) > 6 months on dialysis recovered renal function; 10 of 26 (38{\%}) with > 10 ml/min vs three of 28 (11{\%}) with ≤ 10 ml/min of creatinine clearance (both P < 0.05). Quality of response after autotransplant was also significant: 12 of 31 (39{\%}) being greater than partial remission after AT vs one of 21 patients (5{\%}) attaining partial remission or less became independent of dialysis (P < 0.05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course.",
keywords = "Multiple myeloma, Renal failure, Stem cell transplantation",
author = "Lee, {Choon Kee} and M. Zangari and B. Barlogie and A. Fassas and {van Rhee}, F. and R. Thertulien and G. Talamo and F. Muwalla and E. Anaissie and K. Hollmig and G. Tricot",
year = "2004",
month = "4",
doi = "10.1038/sj.bmt.1704440",
language = "English (US)",
volume = "33",
pages = "823--828",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

AU - Lee, Choon Kee

AU - Zangari, M.

AU - Barlogie, B.

AU - Fassas, A.

AU - van Rhee, F.

AU - Thertulien, R.

AU - Talamo, G.

AU - Muwalla, F.

AU - Anaissie, E.

AU - Hollmig, K.

AU - Tricot, G.

PY - 2004/4

Y1 - 2004/4

N2 - To evaluate the role of high-dose melphalan and autologous transplant (AT) in reversing dialysis-dependent renal failure, 59 patients still on dialysis at the time of AT were analyzed. A total of 37 patients had been on dialysis ≤6 months. A 5-year event-free and overall survival rate of all patients after AT was 24 and 36%, respectively. Of 54 patients evaluable for renal function improvement, 13 (24%) became dialysis independent at a median of 4 months after AT (range: 1-16). Dialysis duration ≤ 6 months prior to first AT and pre-transplant creatinine clearance >10 ml/min were significant for renal function recovery: 12 of 36 (33%) ≤ 6 months vs one of 18 patients (6%) > 6 months on dialysis recovered renal function; 10 of 26 (38%) with > 10 ml/min vs three of 28 (11%) with ≤ 10 ml/min of creatinine clearance (both P < 0.05). Quality of response after autotransplant was also significant: 12 of 31 (39%) being greater than partial remission after AT vs one of 21 patients (5%) attaining partial remission or less became independent of dialysis (P < 0.05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course.

AB - To evaluate the role of high-dose melphalan and autologous transplant (AT) in reversing dialysis-dependent renal failure, 59 patients still on dialysis at the time of AT were analyzed. A total of 37 patients had been on dialysis ≤6 months. A 5-year event-free and overall survival rate of all patients after AT was 24 and 36%, respectively. Of 54 patients evaluable for renal function improvement, 13 (24%) became dialysis independent at a median of 4 months after AT (range: 1-16). Dialysis duration ≤ 6 months prior to first AT and pre-transplant creatinine clearance >10 ml/min were significant for renal function recovery: 12 of 36 (33%) ≤ 6 months vs one of 18 patients (6%) > 6 months on dialysis recovered renal function; 10 of 26 (38%) with > 10 ml/min vs three of 28 (11%) with ≤ 10 ml/min of creatinine clearance (both P < 0.05). Quality of response after autotransplant was also significant: 12 of 31 (39%) being greater than partial remission after AT vs one of 21 patients (5%) attaining partial remission or less became independent of dialysis (P < 0.05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course.

KW - Multiple myeloma

KW - Renal failure

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=11144357978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144357978&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704440

DO - 10.1038/sj.bmt.1704440

M3 - Article

C2 - 14767499

AN - SCOPUS:11144357978

VL - 33

SP - 823

EP - 828

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -